Informations générales (source: ClinicalTrials.gov)
Neurofunctional Basis of Emotion Processing: Clinical, Genetic, Biological and Imaging Study in Patients With Schizophrenia and Healthy Relatives of Patients in Comparison With a Control Group (SCHIZOIMAGEN)
Interventional
N/A
Assistance Publique Hopitaux De Marseille (Voir sur ClinicalTrials)
décembre 2015
juin 2019
29 juin 2024
Schizophrenia is an invalidating psychiatric illness with a strong genetic component
characterized by abnormal processing of emotional information. This alteration in emotion
processing has been described in acute as well as in remission phases of the illness. It
has also been found in healthy relatives of patients with schizophrenia and in subjects
at high risk of psychosis. Thus, alterations in emotional information processing are not
only linked to the prognosis but can also be considered as a marker of vulnerability of
schizophrenia. In addition, schizophrenia patients differ from healthy controls in neural
activity in brain regions implicated in emotions processing. However, interpretation of
findings in patients is limited by confounding factors, such as antipsychotic treatments
or alterations due to the course of illness. Also, there is no data concerning genetic
factors (polymorphisms or gene expression) underlying these patterns of cerebral
activation in emotion information processing.
So, the main objective of this study is to compare the cerebral activity of schizophrenia
patients to that of healthy siblings and healthy controls in an emotional processing
task.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Pôle Psychiatrie Centre CHU Conception, Marseille, APHM - 13005 - Marseille - France | Xavier ZENDJIDJIAN, Dr | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Male or female participant, right-handed, aged from 18 to 45 years old
- Haven given their written consent
- DSM-5 (Diagnostic and Statistical Manual of Mental Disorders version 5) diagnosis of
schizophrenia
- Remitted phase (criteria of Andreasen)
- Stable doses of antipsychotics during the last 6 weeks
- No severe somatic illness
- Normal clinical exam
- Inscription to the social security
- Male or female participant, right-handed, aged from 18 to 45 years old
- Haven given their written consent
- DSM-5 (Diagnostic and Statistical Manual of Mental Disorders version 5) diagnosis of
schizophrenia
- Remitted phase (criteria of Andreasen)
- Stable doses of antipsychotics during the last 6 weeks
- No severe somatic illness
- Normal clinical exam
- Inscription to the social security
- Women in genitally active period without contraception
- Women pregnant or breast feeding
- Participants presenting a severe somatic /neurologic condition
- Present/history in the last year of alcohol or drug abuse
- Participating in another clinical study or still in period of exclusion of a
previous clinical trial
- Contraindication to an MRI test (metallic foreign body, pacemaker, heart valve,
chirurgical clip, claustrophobia...)